紫杉醇联合卡铂同步放化疗治疗局部晚期非小细胞肺癌的临床观察

目的观察常规剂量及方法下紫杉醇联合卡铂同步放化疗治疗局部晚期非小细胞肺癌的疗效。方法对24例Ⅲa和Ⅲb期的非小细胞肺癌患者，采用肺内病灶及纵隔淋巴结引流区放射治疗，肿瘤量为60～65Gy／30f。在放疗第1周和第4周同时给予紫杉醇（135mg／m^2），和卡铂（Auc=6mg·ml^-1·min^-1）方案化疗2疗程。结果完全缓解（CR）3例，部分缓解（PR）10例，稳定（sD）5例，进展（PD）6例。总有效率为59．6％，中位生存期（MST）18月，1、2、3年生存率分别为64．3％、30．2％、12％。主要剂量限制性毒性为骨髓抑制，其中主要是Ⅱ～Ⅲ级粒细胞减少，放射治疗的主要副作用为放射性食管炎、放射性肺炎。结论常规剂量、方法下紫杉醇联合卡铂同步放化疗治疗局部晚期非小细胞肺癌放疗化疗毒副作用可以耐受，有望提高局部晚期非小细胞肺癌的疗效。

The clinical observation of concurrent chemoradiation therapy with paclitaxel and carboplatin for locally advanced non-small-cell lung cancer

Objective To investigate the efficacy of concurrent systemic routine dose of paclitaxel/carboplation combined with conventional thoraciec irradiation in locally advanced non-small-cell lung cancer（NSCLC）. Methods 24 cases of the un- resetable stage Ⅲ a and Ⅲ b NSCLC patients were involved in tiffs study. All patients received conventional thoracic irradiation to a total dose of 60 - 65 Gy within 6 weeks, with concurrent paclitaxel 135 mg/m^2 and carboplatin （ Acu = 6 mg/ml^-1 · min^-1 ）in the first and fourth week. Results CR 3 cases,PR 10 cases,SD 5 cases,PD 6 cases were achieved ,with an overall reponse rate of 59.6% and a medium survival time of 18 months. The 1,2 and 3 years survival rate was 64.3% ,30.2% and 12% respectively. The major side effcts of the radiation were radiation esophagitis and radiation pneumonitis. Conclusion Concurrent chemoradiation therapy with paclitaxel and carboplatin is tolerable and gives promising results in the treatment of locally advanced non-small-cell lung cancer（NSCLC）.